Blood

Vol. 146, Issue 11 Issue 11 2025
17
Articles

Articles in this Issue

Good flatmates: immature neutrophils protect bone integrity

Matthias Gunzer Sep 11, 2025 pp. 1259-1260 10.1182/blood.2025030147

Immune dysfunction after cancer remission: scar or disease?

Michael D. Jain, Jonathan Cools-Lartigue Sep 11, 2025 pp. 1255-1257 10.1182/blood.2025029648

Chauhan D, Li G, Hideshima T, et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. <i>Blood</i> . 2003;102(9):3379-3386.

Sep 11, 2025 pp. 1375-1375 10.1182/blood.2025031044

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Bernd B. Zeisig, Chiou-Tsun Tsai, Clemence Virely et al. Sep 11, 2025 pp. 1314-1330 10.1182/blood.2025028560

Abstract Loss-of-function (LoF) mutations frequently found in human cancers are generally intractable by classical small molecule inhibitor approaches. Among them are mutations affec...

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Jeff P. Sharman, Miklos Egyed, Wojciech Jurczak et al. Sep 11, 2025 pp. 1276-1285 10.1182/blood.2024024476

Abstract Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia. We present results from ELEVATE-TN after a median follow-up o...

Inflammatory memory of stem cells: implications for hematologic diseases

Dongchang Zhao, Pavan Reddy Sep 11, 2025 pp. 1265-1275 10.1182/blood.2024028197

Abstract Immunological memory in adaptive and innate immune cells is well characterized, enabling enhanced responses upon secondary challenges. However, it has only been recently app...

ClpP: a new Achilles' heel in myeloma

Antonio Sacco, Aldo M. Roccaro Sep 11, 2025 pp. 1254-1255 10.1182/blood.2025029682

Not in the beginning

Andrew Yee Sep 11, 2025 pp. 1260-1261 10.1182/blood.2025029865

Chavez JC, Dickinson M, Munoz J, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. <i>Blood</i>. 2025;145(20):2303-2311.

Sep 11, 2025 pp. 1374-1374 10.1182/blood.2025031033

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Richard J. Pelzl, Giulia Benintende, Franziska Gsottberger et al. Sep 11, 2025 pp. 1300-1313 10.1182/blood.2024027877

Abstract Immunotherapy has become standard of care in the treatment of diffuse large B-cell lymphoma (DLBCL). Changes in immunophenotypes observed at first diagnosis predict therapy...

Mac-Man clearance of alloreactive T cells in GVHD

Nataliya Prokopenko Buxbaum Sep 11, 2025 pp. 1262-1263 10.1182/blood.2025029647

Bone marrow neutrophil progenitors suppress osteoclast formation in murine cortical and trabecular bone

Tsuyoshi Isojima, Blessing Crimeen-Irwin, Narelle E. McGregor et al. Sep 11, 2025 pp. 1331-1345 10.1182/blood.2025028310

Abstract In inflammation, circulating neutrophils indirectly damage the skeleton by inducing formation of bone-resorbing osteoclasts. However, neutrophil progenitors in marrow have n...

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma

Tommaso Perini, Paola Zordan, Rossella Del Pizzo et al. Sep 11, 2025 pp. 1286-1299 10.1182/blood.2024026340

Abstract Orchestrating key homeostatic functions, mitochondria likely entail cancer vulnerabilities. Moreover, because of their bacterial ancestry, they can release potent immunogeni...

Plasminogen activation and plasmin activity are not necessary to prevent venous thrombosis/thromboembolism

Yaqiu Sang, Marzia Menegatti, Jennifer A. Brody et al. Sep 11, 2025 pp. 1346-1358 10.1182/blood.2025028680

Abstract Suppression of plasminogen activation and/or plasmin activity (PA) reduces blood loss and decreases hemorrhage-related death. However, whether the endogenous PA system is a...

TE-PARPi as a precision weapon against hematologic cancers

Eirini Trompouki Sep 11, 2025 pp. 1257-1259 10.1182/blood.2025030226

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT

Cindy Flamann, Haroon Shaikh, Carina Matos et al. Sep 11, 2025 pp. 1359-1373 10.1182/blood.2023023056

Abstract Graft-versus-host disease (GVHD) ensues as the most common nonrelapse complication after allogeneic hematopoietic cell transplantation (allo-HCT). A pivotal goal in GVHD man...

ELEVATE-ing clinical trial reporting in CLL

Florian Simon, Othman Al-Sawaf Sep 11, 2025 pp. 1253-1254 10.1182/blood.2025029318

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page